• Cyclic guanosine monophosphate (cGMP) levels have been measured in the cerebrospinal fluid of patients with various neurological diseases. The subjects with epilepsy or cerebrovascular diseases do not show any difference from the controls. Moreover, in the CSF of patients having cerebral tumors the levels of cGMP are markedly increased. This change is in line with previous in vitro studies on the increase of cGMP during cell growth and cell proliferation showing that the role of the nucleotide is important for the control of the life cycle of the cell.
Trabucchi M, Cerri C, Spano PF, Kumakura K. Guanosine 3′-5′-Monophosphate in the CSF of Neurological Patients. Arch Neurol. 1977;34(1):12–13. doi:10.1001/archneur.1977.00500130032006
Customize your JAMA Network experience by selecting one or more topics from the list below.